BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Historical Holders from Q2 2019 to Q3 2025

Symbol: BBIO on Nasdaq
Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 193,828,463
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 184,960,254
Holdings value: $9,606,772,497
% of all portfolios: 0.02%
Number of holders: 387
Number of buys: 217
Number of sells: -172
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
VANGUARD GROUP INC	8.68%		$711,821,652		16,484,985		The Vanguard Group	30 Jun 2025
VIKING GLOBAL INVESTORS LP	8.2%	-15%	$825,530,932	-$140,704,733	15,893,934	-14.6%	VIKING GLOBAL INVESTORS LP	14 Nov 2025
KKR Genetic Disorder L.P.	7%	-31%	$476,864,517	-$215,760,000	13,260,971	-31.2%	KKR Genetic Disorder L.P.	12 May 2025
Kumar Neil	5.41%		$376,382,964		10,466,712		NEIL KUMAR	31 Dec 2024

Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	184,960,254	$9,606,772,497	-$158,354,760	$95,310,452	$585,114,262	$51.94	387
2025 Q2	188,818,044	$8,154,464,813	+$171,957,099	$95,078,274	$484,993,166	$43.18	357
2025 Q1	185,173,982	$6,405,659,483	+$325,204,372	$72,291,862	$441,052,155	$34.57	302
2024 Q4	176,645,317	$4,847,193,349	+$87,655,048	$68,033,556	$354,464,324	$27.44	260
2024 Q3	172,596,886	$4,393,814,683	-$68,086,150	$60,246,408	$264,161,420	$25.46	251
2024 Q2	174,953,530	$4,431,556,073	+$57,307,408	$69,984,256	$216,720,947	$25.33	249
2024 Q1	171,539,419	$5,303,582,949	+$162,256,099	$79,223,644	$225,435,028	$30.92	240
2023 Q4	165,715,337	$6,690,573,516	+$142,779,397	$80,602,337	$64,217,522	$40.37	246
2023 Q3	161,102,840	$4,243,730,776	+$304,390,990	$42,848,613	$52,895,583	$26.37	219
2023 Q2	149,815,028	$2,576,329,186	-$39,862,601	$73,795,250	$98,670,016	$17.20	196
2023 Q1	152,372,388	$2,526,139,807	+$155,256,748	$27,808,632	$38,637,658	$16.58	210
2022 Q4	144,623,389	$1,101,997,850	-$14,634,842	$443,484	$1,069,396	$7.62	175
2022 Q3	145,248,661	$1,443,911,522	+$48,733,339	$1,750,000	$1,953,000	$9.94	170
2022 Q2	140,449,294	$1,275,283,327	-$23,547,672	$2,581,000	$5,787,000	$9.08	153
2022 Q1	143,303,557	$1,454,787,082	-$23,988,513	$3,746,000	$7,228,000	$10.15	167
2021 Q4	141,976,495	$2,367,117,577	-$117,448,257	$63,701,308	$108,846,716	$16.68	181
2021 Q3	140,028,398	$6,563,888,337	-$165,004,819	$34,998,500	$18,756,000	$46.87	206
2021 Q2	142,676,491	$8,697,122,835	+$97,636,690	$43,272,000	$18,194,000	$60.96	197
2021 Q1	141,085,070	$8,688,930,801	+$1,238,074,220	$38,743,000	$18,280,000	$61.60	194
2020 Q4	121,079,579	$8,609,553,572	+$172,667,185	$8,027,000	$23,212,000	$71.11	160
2020 Q3	117,841,767	$4,393,419,330	+$21,644,575	$1,647,000	$1,709,000	$37.52	128
2020 Q2	117,300,177	$3,824,660,106	+$145,729,688	$558,000	$23,083,000	$32.61	114
2020 Q1	112,894,365	$3,273,779,385	+$162,480,179	$1,760,000	$9,715,000	$29.00	93
2019 Q4	100,520,271	$3,523,336,508	+$149,163,509			$35.05	85
2019 Q3	103,303,295	$2,217,864,724	+$112,320,073			$21.47	75
2019 Q2	99,927,998	$2,695,534,750	+$2,695,534,740			$26.97	60